Passions

Sports

CrossFit

Concerts

 

Experience

Viking Therapeutics Announces $632.5 Million Public Offering of Common Stock

March 4, 2024

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Read more

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Madison (JJ) Meng
Associate, San Francisco
Peter A. Haddad
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Wyatt Kernell
Associate, Colorado
Madhuri Roy
Partner, Palo Alto
Randy Sabett
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Xander Lee
Partner, Los Angeles Santa Monica

Related Practices & Industries

Sagimet Biosciences – $112.5 Million Follow-On Offering

January 30, 2024

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.

Related contacts

John McKenna
Partner, Palo Alto
Natalie Karam
Partner, Palo Alto
Denny Won
Partner, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
David D. Kim
Associate, San Francisco
Nicholas Yacoubian
Associate, Palo Alto
Victoria Comesañas
Associate, Palo Alto

Related Practices & Industries

CG Oncology Announces Upsized $437 Million IPO

January 29, 2024

Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led the Cooley team advising the underwriters.

Related contacts

Charlie Kim
Partner, San Diego
Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco

Related Practices & Industries

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington, DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington, DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington, DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Paralegal Specialist, Boston

Related Practices & Industries

Vistagen Therapeutics – $100 Million Follow-on Offering of Common Stock, Pre-Funded Warrants and Two Tranches of Common Stock Warrants

October 4, 2023

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Charlie Kim
Partner, San Diego
Courtney M.W. Tygesson
Partner, Chicago
Christine Turner
Associate, Colorado
Jesse Schulman
Associate, Washington, DC
Mike Lam
Associate, Los Angeles Santa Monica
Carley Cruea
Associate, Washington, DC

Related Practices & Industries

View more

He has unbelievable firepower and work ethic. Denny is a fantastic partner.

Chambers USA, 2024

Denny has an amazing work ethic and he provides seamless, flawless execution on extremely tight timelines.

Chambers USA, 2023

Admissions and credentials

California

New York

Rankings and accolades

Chambers USA: Capital Markets: Debt & Equity (California and Nationwide – Western United States) (2024)

Chambers USA: Up and Coming – Capital Markets: Debt & Equity (California and Nationwide – Western United States) (2023)

Chambers USA: Associate to Watch – Capital Markets: Debt & Equity (California and Nationwide – Western United States) (2021 – 2022)

Memberships and affiliations

New York State Bar Association